FDA guidance
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection…
FDA guidance · Final · issued Oct 22, 2014
Key facts
| Title | Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Oct 22, 2014 |
| Center | Office of Regulatory Affairs |
| Issuing office | Center for Veterinary Medicine, Office of Regulatory Affairs, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Animal & Veterinary, Biologics, Drugs |
| Topics | Postmarket, Investigation & Enforcement |
| Docket number | FDA-2013-D-0710 |
| Comments close | Sep 1, 2013 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents